3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Salivary Gland Neoplasms
3
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
20
Docetaxel
8
Carboplatin
8
Fluorouracil
6
Cisplatin
6
Nivolumab
5
fludarabine
4
Trastuzumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
durvalumab
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
tisotumab vedotin
2
spartalizumab
2
belinostat
2
adavosertib
2
X-Rays
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
trastuzumab deruxtecan
×
Head & Neck
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled